Skip to main content

MWG Caph Ltd

SEC CIK
0002111120
Latest filing
Feb 17, 2026

The latest 13F from MWG Caph Ltd covers Q4 2025 (filed Feb 17, 2026): 3 long positions worth $72.4M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Beam Therapeutics Inc. (BEAM) at 48.5%. Livermore has 1 filing on Form 13F from this institution, going back to Q4 2025.

What changed in Q4 2025

The five largest holdings this quarter.

MWG Caph Ltd did not file a 13F for Q3 2025, so this quarter cannot be compared with the previous one.

Top 5 holdings

Share of this quarter's portfolio value

  1. BEAMBeam Therapeutics Inc.
    48.5%$35.1MHistory
  2. LYELLyell Immunopharma, Inc.
    42.9%$31.0MHistory
  3. PRMEPrime Medicine, Inc.
    8.6%$6.22MHistory

Metrics

13F metrics for Q4 2025, computed only from the numbers in the filings. Definitions below.

Portfolio value
$72.4M
No prior quarter to compare
Positions
3
No prior quarter to compare
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
–
No prior quarter to compare
Average holding period
1.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2025), so positions held before then are understated.

13F filings by quarter

Only Q4 2025 so far.

13F filings of MWG Caph Ltd by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q4 2025Feb 17, 20263$72.4MBEAMLYELPRME–SEC

13D and 13G filings

Companies where MWG Caph Ltd reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

MWG Caph Ltd does not currently report owning 5% or more of any company.

Latest filings

1 filing on file made by MWG Caph Ltd or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by MWG Caph Ltd
CompanyFiled (ET)FormStakeChangeEvent dateFiling
LYELLyell Immunopharma, Inc.May 11, 202611:12 AM ET13G/A4.30%1.01M shares–Below 5%Mar 31, 2026SEC